Adimuplan 50 mg, filmomhulde tabletten

Χώρα: Ολλανδία

Γλώσσα: Ολλανδικά

Πηγή: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Αγόρασέ το τώρα

Δραστική ουσία:

SITAGLIPTINEHYDROCHLORIDE 1-WATER 56,68 mg/stuk SAMENSTELLING overeenkomend met ; SITAGLIPTINE 50 mg/stuk

Διαθέσιμο από:

Sandoz B.V. Veluwezoom 22 1327 AH ALMERE

INN (Διεθνής Όνομα):

SITAGLIPTINEHYDROCHLORIDE 1-WATER 56,68 mg/stuk SAMENSTELLING overeenkomend met ; SITAGLIPTINE 50 mg/stuk

Φαρμακοτεχνική μορφή:

Filmomhulde tablet

Σύνθεση:

CALCIUMWATERSTOFFOSFAAT 0-WATER (E 341) ; CELLULOSE, MICROKRISTALLIJN (E 460(i)) ; CROSCARMELLOSE NATRIUM (E 468) ; HYPROLOSE (E 463) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE GEEL (E 172) ; IJZEROXIDE ROOD (E 172) ; MACROGOL 6000 ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMSTEARYLFUMARAAT ; TALK (E 553 B) ; TITAANDIOXIDE (E 171), CALCIUMWATERSTOFFOSFAAT 0-WATER (E 341) ; CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSCARMELLOSE NATRIUM (E 468) ; HYPROLOSE (E 463) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE GEEL (E 172) ; IJZEROXIDE ROOD (E 172) ; MACROGOL 6000 ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMSTEARYLFUMARAAT ; TALK (E 553 B) ; TITAANDIOXIDE (E 171)

Οδός χορήγησης:

Oraal gebruik

Ημερομηνία της άδειας:

1900-01-01

Φύλλο οδηγιών χρήσης

                                Sandoz B.V.
Page 1/7
Adimuplan
®
25, 50, 100mg, filmomhulde tabletten
RVG 125344-45-46
1313-V5
1.3.1.3 Bijsluiter
Juli 2022
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ADIMUPLAN 25 MG, FILMOMHULDE TABLETTEN
ADIMUPLAN 50 MG, FILMOMHULDE TABLETTEN
ADIMUPLAN 100 MG, FILMOMHULDE TABLETTEN
Sitagliptin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What {[Nationally completed name]} is and what it is used for
2.
What you need to know before you take {[Nationally completed name]}
3.
How to take {[Nationally completed name]}
4.
Possible side effects
5.
How to store {[Nationally completed name]}
6.
Contents of the pack and other information
1.
WHAT {[NATIONALLY COMPLETED NAME]} IS AND WHAT IT IS USED FOR
{[Nationally completed name]} contains the active substance
sitagliptin which is a member of a class
of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4
inhibitors) that lowers blood sugar levels
in adult patients with type 2 diabetes mellitus.
This medicine helps to increase the levels of insulin produced after a
meal and decreases the amount of
sugar made by the body.
Your doctor has prescribed this medicine to help lower your blood
sugar, which is too high because of
your type 2 diabetes. This medicine can be used alone or in
combination with certain other medicines
(insulin, metformin, sulphonylureas, or glitazones) that lower blood
sugar, which you may already be
taking for your diabetes together with a food and exercise plan.
What is type 2 diabetes?
Type 2 diabetes is a condition in which y
                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Αρχείο Π.Χ.Π.

                                Sandoz B.V.
Page 1/21
Adimuplan 25, 50, 100 mg, filmomhulde tabletten
RVG 125344-45-46
1311-V5
1.3.1.1 Summary of Product Characteristics
Mei 2022
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Adimuplan 25 mg, filmomhulde tabletten
Adimuplan 50 mg, filmomhulde tabletten
Adimuplan 100 mg, filmomhulde tabletten
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
{[NATIONALLY COMPLETED NAME] 25 MG FILM-COATED TABLETS}:
Each
film-coated
tablet
contains
sitagliptin
hydrochloride
monohydrate
equivalent
to
25
mg
sitagliptin.
{[NATIONALLY COMPLETED NAME] 50 MG FILM-COATED TABLETS}:
Each
film-coated
tablet
contains
sitagliptin
hydrochloride
monohydrate
equivalent
to
50
mg
sitagliptin.
_ _
{[NATIONALLY COMPLETED NAME] 100 MG FILM-COATED TABLETS}:
Each
film-coated
tablet
contains
sitagliptin
hydrochloride
monohydrate
equivalent
to
100
mg
sitagliptin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
{[NATIONALLY COMPLETED NAME] 25 MG FILM-COATED TABLETS}:
Pink, round, biconvex film-coated tablet debossed with “ST 25” on
one side; diameter 5.7 – 6.6 mm.
{[NATIONALLY COMPLETED NAME] 50 MG FILM-COATED TABLETS}:
Light pink, round, biconvex film-coated tablet debossed with “ST
50” on one side; diameter 7.7 – 8.6
mm.
{[NATIONALLY COMPLETED NAME] 100 MG FILM-COATED TABLETS}:
Light brown, round, biconvex film-coated tablet debossed with “ST
100” on one side; diameter 9.7 –
10.6 mm.
4.
CLINICAL PARTICULARS
Sandoz B.V.
Page 2/21
Adimuplan 25, 50, 100 mg, filmomhulde tabletten
RVG 125344-45-46
1311-V5
1.3.1.1 Summary of Product Characteristics
Mei 2022
4.1
THERAPEUTIC INDICATIONS
For adult patients with type 2 diabetes mellitus, {[Nationally
completed name]} is indicated to
improve glycaemic control:
as monotherapy
•
in patients inadequately controlled by diet and exercise alone and for
whom metformin is
inappropriate due to contraindications or intolerance.
as dual oral therapy in combination with
•
metformin when diet and exercise plus metformin alone do 
                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Προβολή ιστορικού εγγράφων